A phase IV, single center pilot study using alemtuzumab (Campath-1H) induction combined with prednisone-free, calcineurin-inhibitor-free immunosuppression in kidney transplantation

Trial Profile

A phase IV, single center pilot study using alemtuzumab (Campath-1H) induction combined with prednisone-free, calcineurin-inhibitor-free immunosuppression in kidney transplantation

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 28 Oct 2015

At a glance

  • Drugs Alemtuzumab (Primary) ; Mycophenolate mofetil; Sirolimus; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms Cell220
  • Most Recent Events

    • 23 Oct 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 04 May 2011 Five-year results presented at the American Transplant Congress -- 11th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
    • 12 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top